Approval · Notice of Compliance 37978 · 2026
DEVATIS TOFACITINIB: Notice of Compliance 37978
Issued July 21, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 37978
- Date
- July 21, 2026
- Company
- Devatis Canada Inc.Saint John, New Brunswick, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Other
- Canadian reference product
- XELJANZ
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| DEVATIS TOFACITINIB | 02570173 | Approved |
| DEVATIS TOFACITINIB | 02570181 | Approved |
Medicinal ingredients
- TOFACITINIB CITRATE 5 MG per TAB
- TOFACITINIB CITRATE 10 MG per TAB